Markets:

Overview

News

Currencies

International

Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

52.23 -1.22 (-2.28%)

Streaming Delayed Price Updated: 2:55 PM EDT, Sep 10, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2 3 4 5 6 7 8 9

...

35 36 Next >

Why CRISPR Therapeutics Stock Rocked the Market Last Month ↗

September 08, 2026

The company had fallen out of investor favor; its recovery was impressive.

Via The Motley Fool

Where Will CRISPR Therapeutics Stock Be in 5 Years? ↗

September 08, 2026

CRISPR's expanding pipeline could unlock significantly more value by 2031.

Via The Motley Fool

2 Reasons CRISPR Therapeutics Stock Could Soar in the Final 4 Months of 2026 ↗

September 02, 2026

We'll know a little more about the company's prospects by the end of the year.

Via The Motley Fool

CRISPR Therapeutics Stock Is Up Only 8% This Year. Is Cathie Wood's Bet on the Gene-Editing Stock Dead Money? ↗

August 21, 2026

This year, the biotech stock has underperformed both the Nasdaq Biotechnology Index and the S&P 500.

Via The Motley Fool

Topics ETFs Stocks

Vertex Pharmaceuticals' Rally Has a New Engine -- and Wall Street Thinks the Best Is Still Ahead ↗

August 20, 2026

Don't bet against Vertex Pharmaceuticals in cystic fibrosis.

Via The Motley Fool

Morgan Stanley Nearly Doubled Its Price Target for CRISPR Therapeutics. Is the Gene-Editing Stock a No-Brainer Buy? ↗

July 30, 2026

The next six months may be decisive for the biotech.

Via The Motley Fool

3 Stocks With the Most Upside by the End of 2026 ↗

July 30, 2026

Analysts remain optimistic that the market will view upcoming catalysts in a bullish light.

Via The Motley Fool

Topics Workforce

3 Mid-Cap Growth Stocks With Monstrous Long-Term Upside ↗

July 28, 2026

These stocks have market caps below $5 billion, but they could be much more valuable in the future.

Via The Motley Fool

Cathie Wood's $362 Million CRISPR Therapeutics Bet Isn't Just Bold -- It's Backed by a Catalyst Many Investors Are Underrating ↗

July 22, 2026

This particular position isn't rooted solely in the science you've heard most about from the biopharma company so far.

Via The Motley Fool

Topics ETFs

Cathie Wood Is Buying This Up-and-Coming Biotech Stock. Should You Follow Her Lead? ↗

July 20, 2026

Beam Therapeutics' growing pipeline could reward patient investors.

Via The Motley Fool

3 Reasons to Buy CRISPR Therapeutics Stock ↗

July 10, 2026

The company's innovative qualities may pay rich dividends down the road.

Via The Motley Fool

Vertex’s Crinetics Deal Balances Growth with Integration Risk ↗

July 08, 2026

Vertex Pharmaceuticals will acquire Crinetics Pharmaceuticals for $10 billion at $85 per share, adding the approved drug PALSONIFY and pipeline candidate Atumelant to expand beyond its cystic fibrosis...

Via MarketBeat

A New CRISPR "DNA Shredder" Could Change Gene-Editing -- What It Means for CRISPR Therapeutics ↗

July 08, 2026

This new technology could one day significantly expand the market for gene-editing biotechs.

Via The Motley Fool

Over 2 Billion Reasons to Love CRISPR Therapeutics Right Now ↗

July 07, 2026

There's more to young biopharma companies than their numbers, but those numbers are still an important part of each investment thesis.

Via The Motley Fool

CRISPR Therapeutics vs. Viking Therapeutics: Is a Gene-Editing or Weight Loss Focused Stock Is a Better Buy in 2026? ↗

July 07, 2026

One has FDA approval and revenue; the other is pre-commercial but debt-free. Both face distinct risks that could reshape your biotech bet.

Via The Motley Fool

CRISPR Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? ↗

July 06, 2026

One company leads in gene-editing approvals, while the other targets surging demand in metabolic treatments. Here’s how their financials and risk profiles compare.

Via The Motley Fool

CRISPR Therapeutics AG vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? ↗

June 27, 2026

From gene-editing breakthroughs to blockbuster cystic fibrosis drugs, these two industry leaders present sharply contrasting financials and risk profiles.

Via The Motley Fool

The Best Stocks to Invest $1,000 in Right Now ↗

June 22, 2026

Exploring some of the top bargains in a multi-trillion-dollar industry.

Via The Motley Fool

Why CRISPR Therapeutics Stock Has Been on a Roller-Coaster Ride This Year ↗

June 18, 2026

The opportunity is enormous, but uncertainty remains.

Via The Motley Fool

The Best Biotech Stocks to Buy in 2026 ↗

June 17, 2026

They have at least one thing in common: An exciting pipeline.

Via The Motley Fool

Topics ETFs

Here's How I'd Invest $10,000 Right Now ↗

June 17, 2026

My strategy involves focusing on dividends, growth, and also taking on some calculated risk.

Via The Motley Fool

CRISPR Therapeutics Has $2.4 Billion in Cash and an Approved Drug. Why Is Its Stock Trading Nearly 40% Below the Wall Street Consensus? ↗

June 08, 2026

The company seems to be doing everything it's supposed to be doing; the stock just isn't responding.

Via The Motley Fool

CRISPR Therapeutics Stock Is Absurdly Cheap -- Here's Why Analysts See 437% Upside Potential ↗

June 03, 2026

Its revolutionary CASGEVY treatment could be a sign of what's to come.

Via The Motley Fool

Eli Lilly Just Proved Gene Editing Could Be Pharma's Next Gold Rush -- but CRISPR Therapeutics Investors Should Watch Out ↗

June 03, 2026

Eli Lilly's pipeline is an embarrassment of riches.

Via The Motley Fool

CRISPR Therapeutics' Secret Weapon That Many Investors Are Overlooking ↗

June 01, 2026

This little-discussed pipeline program could prove to be a big success.

Via The Motley Fool

CRISPR Therapeutics vs. Editas Medicine: Which Gene Editing Stock Is a Better Buy in 2026? ↗

May 31, 2026

One company dominates with an approved therapy, while the other bets on in vivo innovation. See how their financials and risk profiles stack up for 2026.

Via The Motley Fool

Better Gene-Editing Stock: CRISPR Therapeutics or Beam Therapeutics? ↗

May 25, 2026

Are there significant gains ahead for one (or both) of these innovative biotechs?

Via The Motley Fool

The Best Stocks to Invest $3,000 In Right Now ↗

May 19, 2026

Not every high-potential name costs a fortune to step into.

Via The Motley Fool

CRISPR Therapeutics Enters 'Second Phase' as CASGEVY Momentum Builds, Pipeline Data Looms ↗

May 15, 2026

CRISPR Therapeutics (NASDAQ:CRSP) Chief Executive Officer Sam Kulkarni said the company is entering a “second phase” as it moves beyond the initial launch of CASGEVY and prepares for data from multiple...

Via MarketBeat

Topics Intellectual Property

1 Top Wall Street Analyst Thinks CRISPR Therapeutics Could More Than Double. Should You Buy the Stock Hand Over Fist? ↗

May 11, 2026

The biotech's innovative platform could pay off.

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 8 9

...

35 36 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.